(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $3.64
Utstedt: 13 feb 2024 @ 21:55
Avkastning: 2.61%
Forrige signal: feb 9 - 19:51
Forrige signal:
Avkastning: -3.84 %
Live Chart Being Loaded With Signals
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders...
Stats | |
---|---|
Dagens volum | 155 947 |
Gjennomsnittsvolum | 458 451 |
Markedsverdi | 216.13M |
EPS | $0 ( 2024-04-01 ) |
Neste inntjeningsdato | ( $-0.580 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.340 |
ATR14 | $0.00600 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Demopulos Gregory A Md | Buy | 725 000 | Stock Option (right to buy) |
2024-04-25 | Jacobsen Michael A | Buy | 100 000 | Stock Option (right to buy) |
2024-04-25 | Cancelmo Peter B | Buy | 100 000 | Stock Option (right to buy) |
2023-11-17 | Demopulos Gregory A Md | Buy | 15 000 | Common Stock |
2023-11-15 | Demopulos Peter A Md | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
98.87 |
Last 99 transactions |
Buy: 4 085 039 | Sell: 554 578 |
Volum Korrelasjon
Omeros Corp Korrelasjon
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Omeros Corp Korrelasjon - Valuta/Råvare
Omeros Corp Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-952 000 (0.00 %) |
EPS: | $0.460 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $3.12 |
Financial Reports:
No articles found.
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.